Assertio Holdings, Inc.

NasdaqCM:ASRT Voorraadrapport

Marktkapitalisatie: US$98.2m

Assertio Holdings Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Assertio Holdings's earnings have been declining at an average annual rate of -12.6%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been declining at an average rate of 3.1% per year.

Belangrijke informatie

-12.6%

Groei van de winst

30.7%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie6.0%
Inkomstengroei-3.1%
Rendement op eigen vermogen-261.1%
Nettomarge-261.1%
Volgende winstupdate11 Nov 2024

Recente prestatie-updates uit het verleden

Recent updates

Is Assertio Holdings (NASDAQ:ASRT) Using Debt Sensibly?

Sep 25
Is Assertio Holdings (NASDAQ:ASRT) Using Debt Sensibly?

Assertio Holdings, Inc. (NASDAQ:ASRT) Not Doing Enough For Some Investors As Its Shares Slump 30%

Aug 19
Assertio Holdings, Inc. (NASDAQ:ASRT) Not Doing Enough For Some Investors As Its Shares Slump 30%

There's No Escaping Assertio Holdings, Inc.'s (NASDAQ:ASRT) Muted Revenues Despite A 36% Share Price Rise

Jul 04
There's No Escaping Assertio Holdings, Inc.'s (NASDAQ:ASRT) Muted Revenues Despite A 36% Share Price Rise

Assertio Holdings, Inc. (NASDAQ:ASRT) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

May 07
Assertio Holdings, Inc. (NASDAQ:ASRT) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

Does Assertio Holdings (NASDAQ:ASRT) Have A Healthy Balance Sheet?

Apr 18
Does Assertio Holdings (NASDAQ:ASRT) Have A Healthy Balance Sheet?

Improved Revenues Required Before Assertio Holdings, Inc. (NASDAQ:ASRT) Stock's 26% Jump Looks Justified

Mar 13
Improved Revenues Required Before Assertio Holdings, Inc. (NASDAQ:ASRT) Stock's 26% Jump Looks Justified

We Think Assertio Holdings (NASDAQ:ASRT) Can Stay On Top Of Its Debt

Apr 26
We Think Assertio Holdings (NASDAQ:ASRT) Can Stay On Top Of Its Debt

Is There An Opportunity With Assertio Holdings, Inc.'s (NASDAQ:ASRT) 23% Undervaluation?

Mar 02
Is There An Opportunity With Assertio Holdings, Inc.'s (NASDAQ:ASRT) 23% Undervaluation?

Assertio Holdings Looks Good To Rebound After Recent Price Plunge

Sep 07

Assertio Holdings: Substantial Upside

Aug 21

Assertio Therapeutics Q2 2022 Earnings Preview

Aug 05

Assertio Holdings: Management Still Swimming Against The Tide

Jun 10

Assertio's Phenomenal Turnaround

May 19

Assertio Holdings: Recent Breakout To Lead To Sustained Gains

Apr 07

Assertio's Digital Strategy Looks To Be Paying Off

Jan 21

Assertio shares rise on Q1 revenue strength, provides FY forecast

May 07

Opbrengsten en kosten

Hoe Assertio Holdings geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NasdaqCM:ASRT Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 24132-345814
31 Mar 24142-333714
31 Dec 23152-332703
30 Sep 23169-186602
30 Jun 2316898551
31 Mar 2316297550
31 Dec 22156110480
30 Sep 2213926350
30 Jun 2213025410
31 Mar 221213430
31 Dec 21111-1460
30 Sep 21110-30690
30 Jun 21119-44752
31 Mar 21114-65903
31 Dec 20108-281044
30 Sep 20135-19610610
30 Jun 20156-18311610
31 Mar 20192-1621139
31 Dec 19230-21711010
30 Sep 19157-491117
30 Jun 19180-41087
31 Mar 19186-111168
31 Dec 18256371208
30 Sep 18364281437
30 Jun 18381-361607
31 Mar 18419-4217910
31 Dec 17381-10220314
30 Sep 17410-11420322
30 Jun 17425-11120530
31 Mar 17442-9520632
31 Dec 16456-8920533
30 Sep 16443-7519430
30 Jun 16437-7419224
31 Mar 16415-8519722
31 Dec 15343-7617918
30 Sep 154265017013
30 Jun 153736814810
31 Mar 153461021237
31 Dec 143901321217
30 Sep 14236791197
30 Jun 14222791197
31 Mar 14185671127
31 Dec 13134431058

Kwaliteitswinsten: ASRT is currently unprofitable.

Groeiende winstmarge: ASRT is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: ASRT is unprofitable, and losses have increased over the past 5 years at a rate of 12.6% per year.

Versnelling van de groei: Unable to compare ASRT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: ASRT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).


Rendement op eigen vermogen

Hoge ROE: ASRT has a negative Return on Equity (-261.15%), as it is currently unprofitable.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden